Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

被引：0
|
作者：
Zandberg, D. [1 ]
Algazi, A. [2 ]
Jimeno, A. [3 ,4 ,5 ]
Good, J. S. [6 ]
Fayette, J. [7 ]
Bouganim, N. [8 ]
Ready, N. [9 ]
Clement, P. M. [10 ]
Goswmi, T. [11 ]
Jarkowski, A. [11 ]
Armstrong, J. M. [11 ]
Asubonteng, K. [11 ]
Melillo, G. [11 ]
Mesia, R. [12 ]
机构：
[1] Univ Maryland, Greenebaum Comprehens Canc Ctr, Hematol Oncol, Baltimore, MD 21201 USA
[2] Univ Calif San Francisco, Oncol, San Francisco, CA 94143 USA
[3] Univ Colorado, Canc Ctr, Dept Med Oncol, Colorado City, CO USA
[4] Univ Colorado, Canc Ctr, Dept Otolaryngol, Colorado City, CO USA
[5] Gates Ctr Regenerat Med, Colorado City, CO USA
[6] Queen Elizabeth Hosp, Inst Head & Neck Studies & Educ, Oncol, Birmingham, W Midlands, England
[7] Univ Lyon, Canc Ctr Ctr Leon Berard, Clin Oncol, Lyon, France
[8] McGill Univ, Hlth Ctr, Dept Oncol, Montreal, PQ, Canada
[9] Duke Univ, Med Ctr, Med Oncol, Durham, NC USA
[10] Univ Hosp Leuven, Dept Oncol, Leuven, Belgium
[11] AstraZeneca, Immunooncol GMD, Gaithersburg, MD USA
[12] Univ Barcelona, Catalan Inst Oncol, Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)
    Jose Echarri, Maria
    Lopez-Martin, Ana
    Hitt, Ricardo
    CANCERS, 2016, 8 (03)
  • [22] Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
    Ji, Dongmei
    Sang, Youzhou
    Liu, Xin
    Guo, Yanjing
    Yang, Yanan
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
    Zandberg, Dan P.
    Algazi, Alain P.
    Jimeno, Antonio
    Good, James S.
    Fayette, Jerome
    Bouganim, Nathaniel
    Ready, Neal E.
    Clement, Paul M.
    Even, Caroline
    Jang, Raymond W.
    Wong, Stuart
    Keilholz, Ulrich
    Gilbert, Jill
    Fenton, Moon
    Brana, Irene
    Henry, Stephanie
    Remenar, Eva
    Papai, Zsuzsanna
    Siu, Lillian L.
    Jarkowski, Anthony
    Armstrong, Jon M.
    Asubonteng, Kobby
    Fan, Jean
    Melillo, Giovanni
    Mesia, Ricard
    EUROPEAN JOURNAL OF CANCER, 2019, 107 : 142 - 152
  • [24] Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
    Jove, M.
    Brana, I.
    Oliva Bernal, M.
    Hernando-Calvo, A.
    Erasun Lecuona, C.
    Assaf Pastrana, J. D.
    Bazan Peregrino, M.
    Mato-Berciano, A.
    Maliandi, M. V.
    Torres-Manjon, S.
    Martinez De Villareal, J.
    Real, F. X.
    Nuciforo, P. G.
    Alemany, R.
    Capella, G.
    Blasi, E.
    Blasco, C.
    Cascallo Piqueras, M.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1112 - S1112
  • [25] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    Soulieres, D.
    Tahara, M.
    De Castro, G., Jr.
    Psyrri, A.
    Rotllan, N. Baste
    Neupane, P. C.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Roy, A.
    Cheng, J.
    Jin, F.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Sequential Treatment Use in Clinical Practice for US Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Zheng, D.
    Black, C. M.
    Hair, G. M.
    Bidadi, B.
    Lerman, N.
    Ai, L.
    Zion, A.
    Zou, L.
    Gao, W.
    Hanna, G. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E34
  • [28] PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the US
    Hanna, Glenn J.
    Zheng, Dandan
    Gao, Wei
    Hair, Gleicy M.
    Ai, Lei
    Song, Yan
    Lerman, Nati
    Bidadi, Behzad
    Zion, Abigail
    Zou, Lin
    Tang, Yuexin
    Wang, Liya
    Merchant, Sanjay
    Black, Christopher M.
    ORAL ONCOLOGY, 2025, 161
  • [29] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Villacampa Javierre, G.
    Garralda, E.
    Gutierrez, R.
    Feliu, B.
    Martinez, S.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [30] Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
    Zhu, Guopei
    Zhang, Lin
    Dou, Shengjin
    Li, Rongrong
    Li, Jiang
    Ye, Lulu
    Jiang, Wen
    Dong, Minjun
    Ruan, Min
    Yang, Wenjun
    Zhang, Chenping
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
12345